{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-122434","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.154021+00:00","generated_at":"2026-06-16T08:20:56.546323+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Enanta sells 54.5% of MAVYRET royalties to OMERS for $200M; non-dilutive funding","bullets":["Sold 54.5% of future royalty payments on MAVYRET/MAVIRET worldwide sales to OMERS Life Sciences for $200M.","OMERS receives royalty payments from July 2023 through June 2032, capped at 1.42x purchase price ($284M).","Enanta retains 45.5% of royalties until cap is reached, then 100% reverts to Enanta.","Proceeds to fund clinical development of pipeline therapies for viral infections; transaction is non-dilutive."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-122434","json":"https://secwatch.observer/filing/0001193125-23-122434.json","markdown":"https://secwatch.observer/filing/0001193125-23-122434.md","text":"https://secwatch.observer/filing/0001193125-23-122434.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000119312523122434/0001193125-23-122434-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000119312523122434/d500394d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T08:20:56.546323+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"35778294b9f490f501d5cf59965047250988c8ca","claim":"ENANTA PHARMACEUTICALS INC entered into Royalty Purchase Agreement with OCM Life Sciences Portfolio LP, an investment vehicle of OMERS valued at $200 million (effective 2023-04-25).","evidence_excerpt":"On April 25, 2023, Enanta Pharmaceuticals, Inc. and OCM Life Sciences Portfolio LP, an investment vehicle of OMERS, one of Canada’s largest defined benefit pension plans, entered into a Royalty Purchase Agreement (the “ Agreement ”), pursuant to which Enanta sold to OMERS 54.5% of Enanta’s royalty interest in respect of worldwide net sales of MAVYRET ® /MAVIRET ® (and any other royalty-bearing products that may contain glecaprevir). The purchase price paid to Enanta was $200 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1177648/000119312523122434/0001193125-23-122434-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"OCM Life Sciences Portfolio LP, an investment vehicle of OMERS"},{"label":"Value","value":"$200 million"},{"label":"Effective","value":"2023-04-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}